Indivior (NASDAQ:INDV) Director Stuart Kingsley Buys 940 Shares

Indivior PLC (NASDAQ:INDV) Director Stuart Kingsley bought 940 shares of the company’s stock in a transaction on Friday, March 6th. The shares were acquired at an average cost of $31.86 per share, for a total transaction of $29,948.40. Following the completion of the acquisition, the director directly owned 5,582 shares of the company’s stock, valued at $177,842.52. This trade represents a 20.25% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Indivior Stock Performance

Shares of NASDAQ:INDV traded up $1.74 during trading on Wednesday, reaching $35.08. The company had a trading volume of 815,349 shares, compared to its average volume of 1,916,924. The firm’s fifty day moving average is $33.99 and its 200 day moving average is $30.51. The firm has a market capitalization of $4.39 billion, a PE ratio of 21.39 and a beta of 0.83. Indivior PLC has a twelve month low of $8.64 and a twelve month high of $38.00.

Indivior (NASDAQ:INDV) last released its earnings results on Thursday, February 26th. The company reported $0.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.17. The company had revenue of $358.00 million during the quarter, compared to analyst estimates of $305.62 million. Indivior had a negative return on equity of 148.76% and a net margin of 16.85%. Equities analysts predict that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

INDV has been the topic of several recent research reports. Morgan Stanley reaffirmed an “overweight” rating and set a $36.00 target price on shares of Indivior in a report on Wednesday, December 3rd. Northland Securities set a $50.00 price objective on Indivior in a report on Tuesday, January 20th. HC Wainwright raised their price objective on Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a report on Monday, January 12th. Weiss Ratings upgraded shares of Indivior from a “hold (c)” rating to a “buy (b-)” rating in a report on Monday, March 2nd. Finally, Zacks Research lowered shares of Indivior from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 13th. Six investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $39.33.

Institutional Trading of Indivior

Hedge funds have recently bought and sold shares of the stock. Oaktree Capital Management LP raised its holdings in shares of Indivior by 2,241.6% during the third quarter. Oaktree Capital Management LP now owns 257,785,398 shares of the company’s stock worth $6,215,206,000 after purchasing an additional 246,776,273 shares during the last quarter. Divisadero Street Capital Management LP grew its holdings in Indivior by 2,372.5% in the third quarter. Divisadero Street Capital Management LP now owns 3,362,605 shares of the company’s stock valued at $81,072,000 after purchasing an additional 3,226,605 shares during the period. Fuller & Thaler Asset Management Inc. lifted its holdings in Indivior by 101.0% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 6,371,534 shares of the company’s stock valued at $228,611,000 after purchasing an additional 3,201,639 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in Indivior during the 4th quarter worth approximately $82,687,000. Finally, Vanguard Group Inc. raised its stake in Indivior by 57.9% in the 4th quarter. Vanguard Group Inc. now owns 5,473,891 shares of the company’s stock valued at $196,403,000 after purchasing an additional 2,008,078 shares during the last quarter. Hedge funds and other institutional investors own 60.33% of the company’s stock.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.